PRESS RELEASE published on 11/10/2023 at 06:30, 1 year ago Formycon hosts conference call on nine-month figures 2023 and presents at further investor conferences
PRESS RELEASE published on 10/10/2023 at 07:30, 1 year 1 month ago Formycon Ranibizumab Biosimilar FYB201/CIMERLI®1 achieved 25% market share2 in the United States
PRESS RELEASE published on 09/29/2023 at 07:30, 1 year 1 month ago Formycon and Fresenius Kabi announce European Medicines Agency Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate
PRESS RELEASE published on 08/30/2023 at 07:30, 1 year 2 months ago Formycon reports successful first half of 2023
PRESS RELEASE published on 08/29/2023 at 07:30, 1 year 2 months ago Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by the U.S. Food and Drug Administration (FDA)
PRESS RELEASE published on 08/23/2023 at 07:30, 1 year 2 months ago Formycon hosts conference call on financial and earnings position for H1 2023
PRESS RELEASE published on 08/21/2023 at 13:42, 1 year 3 months ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
PRESS RELEASE published on 08/07/2023 at 08:00, 1 year 3 months ago Formycon and Fresenius Kabi secure U.S. License Date for proposed Ustekinumab Biosimilar
PRESS RELEASE published on 07/26/2023 at 07:30, 1 year 3 months ago Formycon reports on the regular Annual General Meeting
PRESS RELEASE published on 06/29/2023 at 07:30, 1 year 4 months ago Formycon announces submission of the biologics license application (BLA) for FYB203, an aflibercept biosimilar candidate to the U.S. Food and Drug Administration (FDA)
Published on 11/21/2024 at 22:05, 1 hour 55 minutes ago Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 2 hours 10 minutes ago Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 3 hours 45 minutes ago Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 3 hours 50 minutes ago For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 20:00, 4 hours ago Victory for New York Homeowners: Petroff Amshen LLP Blocks Lender’s Repeated Foreclosure Attempt
Published on 11/21/2024 at 19:01, 4 hours 59 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 5 hours 24 minutes ago Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 6 hours 1 minute ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 6 hours 8 minutes ago LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 6 hours 8 minutes ago 2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.
Published on 11/21/2024 at 06:58, 17 hours 2 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 4 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 6 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 6 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 16 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
